This year, we are going to be discussing how to navigate the everchanging capital markets outlook and, in particular, to explore how European biotechs can scale growth to either attract big pharma or secure the financial backing they need to follow through to commercialisation. With European companies often failing to get the scale needed to cut through in the US, what are the lessons to be learned?

As markets estimate that c.$300bn of pharma revenue needs to be found, there has never been a better time for biotechs to sharpen their story and get the deal they deserve, nor a better moment for Pharma to fill the looming patent cliff.

This will be the 17th year of the conference, and we are putting together a fantastic agenda of world class speakers from the life sciences and the investment communities that our attendees have learned to expect. The event will close with networking reception drinks, once again kindly sponsored by Cooley and ICG.

Returning to this year’s event by popular demand Optimum will be running ‘Investor speed dating’, bringing some of the most exciting early-stage companies together with leading investors.

Register your interest today!